Curis Total Assets 2006-2021 | CRIS

Curis total assets from 2006 to 2021. Total assets can be defined as the sum of all assets on a company's balance sheet.
Curis Annual Total Assets
(Millions of US $)
2020 $204
2019 $35
2018 $37
2017 $74
2016 $58
2015 $95
2014 $63
2013 $81
2012 $70
2011 $48
2010 $51
2009 $36
2008 $40
2007 $54
2006 $52
2005 $61
Curis Quarterly Total Assets
(Millions of US $)
2021-09-30 $172
2021-06-30 $181
2021-03-31 $191
2020-12-31 $204
2020-09-30 $46
2020-06-30 $45
2020-03-31 $27
2019-12-31 $35
2019-09-30 $42
2019-06-30 $48
2019-03-31 $55
2018-12-31 $37
2018-09-30 $44
2018-06-30 $53
2018-03-31 $61
2017-12-31 $74
2017-09-30 $82
2017-06-30 $64
2017-03-31 $74
2016-12-31 $58
2016-09-30 $66
2016-06-30 $74
2016-03-31 $85
2015-12-31 $95
2015-09-30 $106
2015-06-30 $112
2015-03-31 $119
2014-12-31 $63
2014-09-30 $68
2014-06-30 $74
2014-03-31 $75
2013-12-31 $81
2013-09-30 $79
2013-06-30 $68
2013-03-31 $65
2012-12-31 $70
2012-09-30 $53
2012-06-30 $55
2012-03-31 $55
2011-12-31 $48
2011-09-30 $39
2011-06-30 $43
2011-03-31 $47
2010-12-31 $51
2010-09-30 $54
2010-06-30 $55
2010-03-31 $59
2009-12-31 $36
2009-09-30 $38
2009-06-30 $37
2009-03-31 $41
2008-12-31 $40
2008-09-30 $42
2008-06-30 $46
2008-03-31 $47
2007-12-31 $54
2007-09-30 $54
2007-06-30 $43
2007-03-31 $48
2006-12-31 $52
2006-09-30 $53
2006-06-30 $58
2006-03-31 $60
2005-12-31 $61
2005-09-30 $61
2005-06-30 $64
2005-03-31 $64
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.443B $0.011B
Curis, Inc. is a therapeutic drug development company focusing on cancer, neurological and dermatological disease indications, with technologies that utilize regulatory pathways that control repair and regeneration. Curis' product development involves the use of small molecules or proteins to modulate these pathways. The company has successfully used this technology and product development approach to produce several promising drug product candidates in the fields of cancer, neurological disorders, hair growth, kidney and other diseases, as well as cardiovascular disease.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $121.281B 7.66
Bio-Rad Laboratories (BIO.B) United States $22.443B 45.55
QIAGEN (QGEN) Netherlands $12.681B 21.48
Biohaven Pharmaceutical Holding (BHVN) United States $7.357B 0.00
Arcus Biosciences (RCUS) United States $3.170B 0.00
Emergent Biosolutions (EBS) United States $2.265B 8.14
Myovant Sciences (MYOV) United Kingdom $1.741B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.500B 0.00
Zymeworks (ZYME) Canada $0.902B 0.00
Ambrx Biopharma (AMAM) United States $0.391B 0.00
SQZ Biotechnologies (SQZ) United States $0.337B 0.00
Enzo Biochem (ENZ) United States $0.162B 15.95